Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor

References

• Taylor HC. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 1929;48:204–230.
   Google Scholar
• International Federation of Gynecology and Obstetrics Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971;50:1–7.
   PubMedGoogle Scholar
• Ahmed Sekotory, Ahmed M, Frank Grang Lawton. Borderline ovarian tumours: Current concepts and management. Reviews in Gynaecological Practice 2005;51:39–151.
   Google Scholar
• Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007;25:2928–2937.
   PubMed Web of Science ®Google Scholar
• Tinelli R, Malzoni M, Cosentino F, Perone C, Tinelli A, Malvasi A, Cicinelli E. Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertil Steril 2009;92:736–741.
   PubMed Web of Science ®Google Scholar
• Benito V, Lubrano A, Arencibia O, Medina N, Álvarez Eva E, Andújar M, Falcón Juan M, Falcón O. Serous and mucinous borderline ovarian tumors: Are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol 2010;153:188–192.
   PubMed Web of Science ®Google Scholar
• Strigini FA, Gadducci A, Del Bravo B, Ferdeghini M, Genazzani AR. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol 1996;61:68–72.
   PubMed Web of Science ®Google Scholar
• Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: A systematic review. Obstet Gynecol 2009;113:384–394.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922–929.
   PubMedGoogle Scholar
• van den Akker PA, Aalders AL, Snijders MP, Kluivers KB, Samlal RA, Vollebergh JH, Massuger LF. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses. Gynecol Oncol 2010;116:384–388.
   PubMed Web of Science ®Google Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, Nustad K. Evaluation of risk of malignancy index based on serum CA 125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynecol 1996;103:826–831.
   PubMedGoogle Scholar
• Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93:448–452.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 2009;144:163–167.
   PubMed Web of Science ®Google Scholar
• Zanetta G, Lissoni A, Cha S, Bertalero C, Scalambrino S, Bratina G. Pre-operative morphological and colour Doppler features of borderline ovarian tumours. Br J Obstet Gynaecol 1995;102:990–996.
   PubMedGoogle Scholar
• Emoto M, Udo T, Obama H, Eguchi F, Hachisuga T, Kawarabayashi T. The blood flow characteristics in borderline ovarian tumors based on both color Doppler ultrasound and histopathological analyses. Gynecol Oncol 1998;70:351–357.
   PubMed Web of Science ®Google Scholar
• Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B, Kopolovic J, Novikov I, Ben-Baruch G. CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol 2000;183:541–546.
   PubMed Web of Science ®Google Scholar
• Pascual MA, Tresserra F, Grases PJ, Labastida R, Dexeus S. Borderline cystic tumors of the ovary: Gray-scale and color Doppler sonographic findings. J Clin Ultrasound 2002;30:76–82.
   PubMed Web of Science ®Google Scholar
• Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, Arduini D. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 2005;25:50–59.
   PubMed Web of Science ®Google Scholar
• Aslam N, Tailor A, Lawton F, Carr J, Savvas M, Jurkovic D. Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG 2000;107:1347–1353.
   PubMedGoogle Scholar
• Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol 2005;123 Suppl:S13–S57.
   Google Scholar
• FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics 2009;105:3–4.
   PubMed Web of Science ®Google Scholar
• Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol 2000;191:69–75.
   Google Scholar
• Coumbos A, Sehouli J, Chekerov R, Schaedel D, Oskay-Oezcelik G, Lichtenegger W, Kuehn W; North-Eastern German Society of Gynecological Oncology (NOGGO). Clinical management of borderline tumours of the ovary: Results of a multicentre survey of 323 clinics in Germany. Br J Cancer 2009;100:1731–1738.
   PubMed Web of Science ®Google Scholar
• Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: A quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 2009;142:99–105.
   PubMed Web of Science ®Google Scholar
• Tamakoshi K, Kikkawa F, Shibata K, Tomoda K, Obata NH, Wakahara F, Tokuhashi Y, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol 1996;62:67–72.
   PubMed Web of Science ®Google Scholar
• Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 2000;78:16–20.
   PubMed Web of Science ®Google Scholar
• Eva Kolwijck Chris, MG, Thomas Ş, Johan Bulten, Leon FAG. Massuger. Preoperative CA-125 Levels in 123 Patients with Borderline Ovarian Tumors A Retrospective Analysis and Review of the Literature. Int J Gynecol Cancer 2009;19:1335–1338.
   PubMed Web of Science ®Google Scholar
• Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, Berkowitz RS. Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol 2010;119:462–468.
   PubMed Web of Science ®Google Scholar
• Jie Ren, Zhilan Peng, Kaixuan Yang. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecologic Oncology 2008;110:162–167.
   PubMed Web of Science ®Google Scholar
• Togashi K. Ovarian cancer: The clinical role of US, CT, and MRI. Eur Radiol 2003;13 Suppl 4:L87–104.
   Google Scholar
• McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, et al. Predicting risk of malignancy in adnexal masses. Obstet Gynecol 2010;115:687–694.
   PubMed Web of Science ®Google Scholar
• Ulusoy S, Akbayir O, Numanoglu C, Ulusoy N, Odabas E, Gulkilik A. The risk of malignancy index in discrimination of adnexal masses. Int J Gynaecol Obstet 2007;96:186–191.
   PubMed Web of Science ®Google Scholar
• Manjunath AP, Pratapkumar, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001;81:225–229.
   PubMed Web of Science ®Google Scholar
• Lenhard MS, Mitterer S, Kümper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A. Long-term follow-up after ovarian borderline tumor: Relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol 2009;145:189–194.
   PubMed Web of Science ®Google Scholar